CAPRICOR THERAPEUTICS

19.36

08-November-24 12:04:19

15 minutes delayed

Stocks

+0.51

+2.71%

Today's range

18.66 - 19.58

ISIN

N/A

Source

NASDAQ

Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio

29 Apr 2021 07:00:01 By Nasdaq GlobeNewswire
Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

11 Mar 2021 15:01:00 By Nasdaq GlobeNewswire
Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform

09 Mar 2021 08:15:00 By Nasdaq GlobeNewswire
Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11

04 Mar 2021 08:00:01 By Nasdaq GlobeNewswire
Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines

01 Feb 2021 08:15:00 By Nasdaq GlobeNewswire
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes

19 Jan 2021 08:15:00 By Nasdaq GlobeNewswire
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

12 Jan 2021 08:05:00 By Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.